Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma
oleh: Leanne Kaye, Vy Vuong, Meredith A. Barrett, Elroy Boers, Theresa Guilbert
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-09-01 |
Deskripsi
Abstract Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medication use and may reduce symptom-related disruptions.